Trial Profile
A repeat-dose, open-label, 2-session study to assess the systemic exposure to, and pharmacodynamics of, fluticasone propionate HFA inhalation aerosol 88 mcg administered twice-daily for 28 days delivered via an MDI and valved holding chamber with infant face mask to subjects ages 6 months to <12 months who have experienced 2 or more wheezing episodes in the preceding 6 months.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Asthma; Wheezing
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 23 Nov 2016 New trial record